GBG Forschungs GmbH (German Breast Group)

Industry / private company


Location: Neu-Isenburg, Germany (DE) DE

ISNI: 0000000404572954

ROR: https://ror.org/03c8hnh70

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Everolimus as treatment for breast cancer patients with bone metastases only: Results of the phase II RADAR study (2013) Maass N, Harbeck N, Mundhenke C, Lerchenmueller C, Barinoff J, Lueck HJ, Ettl J, et al. Journal article Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer (2012) Wenners AS, Mehta K, Loibl S, Park H, Mueller B, Arnold N, Hamann S, et al. Journal article Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer (2011) Von Minckwitz G, Schweller K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, et al. Journal article Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial (2010) Witzel I, Loibl S, Von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, et al. Journal article
‹ 1 ... 14 15 16 ›